Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Geetha Pillai

Internal Medicine Leesburg, VA Medical Doctor

NPI 1356335301 CMS profile 242433

19450 Deerfield Avenue, Suite 300, Leesburg, VA 20176

Open in the dashboard

General payments

$5,666

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Geetha Pillai of Leesburg, VA is reported in the CMS Open Payments database as having received $5,666 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,124 79
2024 General $1,554 67
2023 General $1,800 53
2022 General $34 2
2021 General $15 1
2020 General $50 3
2019 General $88 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Geetha Pillai
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Geetha Pillai were reported at $2,124. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Geetha Pillai Internal Medicine median Middle half National median
2019 $88 $159 $48–$570 $163
2020 $50 $119 $33–$402 $114
2021 $15 $135 $37–$521 $132
2022 $34 $141 $42–$496 $149
2023 $1,800 $149 $45–$519 $160
2024 $1,554 $154 $47–$537 $164
2025 $2,124 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,152 36 payments
  2. AbbVie, Inc. $695 35 payments
  3. Stryker Corporation $640 1 payment
  4. Pfizer Inc. $392 15 payments
  5. Amgen Inc. $388 19 payments
  6. AstraZeneca Pharmaceuticals LP $291 16 payments
  7. Astellas Pharma US Inc $286 10 payments
  8. Lilly USA, LLC $249 12 payments
  9. Noah Medical Corporation $242 4 payments
  10. Otsuka America Pharmaceutical, Inc. $145 7 payments
  11. Other $1,185 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,933 206 payments
  2. Travel and Lodging $640 1 payment
  3. Education $93 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $722 26 payments
  2. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $640 1 payment
  3. RYBELSUS $414 19 payments
  4. Wegovy $377 8 payments
  5. Otezla $263 12 payments
  6. NURTEC ODT $246 11 payments
  7. GALAXY $242 4 payments
  8. VRAYLAR $229 12 payments
  9. Veozah $221 9 payments
  10. MOUNJARO $215 10 payments
  11. Other $3,360 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

3,636

Median for Internal Medicine: 777

Drug cost

$478,555

Median for Internal Medicine: $73,373

Branded share of claims

25.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 47 $73,163
Eliquis Apixaban Brand 59 $58,388
Jardiance Empagliflozin Brand 39 $51,697
Ozempic Semaglutide Brand 29 $49,589
Mounjaro Tirzepatide Brand 33 $38,582
Farxiga Dapagliflozin Propanediol Brand 32 $35,620
Tresiba Flextouch U-200 Insulin Degludec Brand 12 $18,939
Breo Ellipta Fluticasone/Vilanterol Brand 45 $18,893
Xarelto Rivaroxaban Brand 17 $17,468
Januvia Sitagliptin Phosphate Brand 22 $16,900

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$196,068

Of which drugs: $50,969

Medicare patients

322

Average age 76

Services billed

3,024

231 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 25%
Osteoporosis 25%
Ischemic heart disease 21%
Chronic kidney disease 21%
Depression 21%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 89 89 $25,866
Vaccine for influenza for injection into muscle 90662 Office 105 111 $8,849
Sarscv2 vac 30mcg trs-suc im 91320 Office 50 52 $7,566

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $255
$255 — —
VRAYLAR
  • AbbVie, Inc. $152
$152 — —
Ozempic
  • Novo Nordisk Inc $98
$98 29 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $90
$90 32 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record